Monitoring and assessing vaccine safety: a European perspective

被引:12
作者
Lopalco, Pier Luigi [1 ]
Johansen, Kari [1 ]
Ciancio, Bruno [1 ]
Gomes, Helena De Carvalho [1 ]
Kramarz, Piotr [1 ]
Giesecke, Johan [1 ]
机构
[1] European Ctr Dis Prevent & Control, Sci Advice Unit, SE-17183 Stockholm, Sweden
关键词
adverse effects; European Union; immunization program; vaccination; vaccine safety; HEPATITIS-B VACCINATION; CAMPAIGN; AUTISM; RISK; MMR;
D O I
10.1586/ERV.10.20
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The success of vaccination programs is an uncontroversial reality in Europe as well as worldwide. On the other hand, the perceived risk of adverse events in the general public is the most important threat for implementing successful vaccination programs in Europe. For this reason, monitoring and assessing vaccine safety is a priority for public health. Vaccine safety is assessed both before and after vaccine authorization. In postmarketing settings, different activities related to vaccine safety usually involve several different stakeholders. In 2005, a new EU agency, the European Centre for Disease Prevention and Control, was established with the aim to strengthen Europe's defences against infectious diseases. Implementing stable links between different stakeholders and defining clear roles in the EU is paramount in order to provide optimal and transparent information on adverse reactions following immunization, with the final goal of increasing compliance to safe and effective vaccination programs.
引用
收藏
页码:371 / 380
页数:10
相关论文
共 23 条
[1]   Hepatitis B vaccination and the risk of multiple sclerosis [J].
Ascherio, A ;
Zhang, SM ;
Hernán, MA ;
Olek, MJ ;
Coplan, PM ;
Brodovicz, K ;
Walker, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :327-332
[2]   Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: How should we raise infant immunization coverage rates? [J].
Balinska, Marta A. .
JOURNAL OF CLINICAL VIROLOGY, 2009, 46 (03) :202-205
[3]   Reporting of vaccine safety data in publications: systematic review [J].
Bonhoeffer, J ;
Zumbrunn, B ;
Heininger, U .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (02) :101-106
[4]   Vaccine Safety Datalink project: A new tool for improving vaccine safety monitoring in the United States [J].
Chen, RT ;
Glasser, JW ;
Rhodes, PH ;
Davis, RL ;
Barlow, WE ;
Thompson, RS ;
Mullooly, JP ;
Black, SB ;
Shinefield, HR ;
Vadheim, CM ;
Marcy, SM ;
Ward, JI ;
Wise, RP ;
Wassilak, SG ;
Hadler, SC ;
Swint, E ;
Hardy, JR ;
Payne, T ;
Immanuel, V ;
Benson, P ;
Draket, J ;
Drew, L ;
Mendius, B ;
Ray, P ;
Lewis, N ;
Fireman, BH ;
Jing, J ;
Wulfsohn, M ;
Lugg, MM ;
Osborne, P ;
Rastogi, S ;
Patriarca, P ;
Caserta, V .
PEDIATRICS, 1997, 99 (06) :765-773
[5]  
*CIOMS, DEV RAT US STAND MED
[6]  
*CIOMS WHO WORK GR, DEF VACC PHARM
[7]  
*COMM MED PROD HUM, GUID COND PHARM VACC
[8]   Vaccinations and the risk of relapse in multiple sclerosis [J].
Confavreux, C ;
Suissa, S ;
Saddier, P ;
Bourdés, V ;
Vukusic, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :319-326
[9]   Vaccines and autism: Evidence does not support a causal association [J].
DeStefano, F. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (06) :756-759
[10]  
DeStefano Frank, 2004, Expert Rev Vaccines, V3, P19, DOI 10.1586/14760584.3.1.19